CAPR Court News: Capricor Therapeutics Securities Fraud Class Action Filed After Clinical Data Issues and 64% Stock Drop – Contact BFA Law Before September 28
Bleichmar Fonti & Auld LLP announced that a class action lawsuit has been filed against Capricor Therapeutics and certain executives for alleged securities fraud. The lawsuit centers on claims that Capricor made false statements regarding the clinical data for Deramiocel, leading to a significant stock drop.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.